CLARITY AD
E125383
UNEXPLORED
CLARITY AD is a pivotal phase 3 clinical trial that evaluated the efficacy and safety of the anti-amyloid Alzheimer’s disease drug lecanemab (Leqembi) in patients with early Alzheimer’s disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.